Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Dannemiller Memorial Educational Foundation and Purdue University School of Pharmacy. The Dannemiller Memorial Educational Foundation is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Physicians
The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s).TM Each physician should claim only those credits that he/she actually spent in the activity.
 
Pharmacists
Purdue University is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmaceutical education. This is a continuing education activity of Purdue, an equal access/equal opportunity university. To receive the 1 contact hour of continuing education credit, pharmacists should complete the activity requirements and evaluation at the conclusion of the monograph. Approval is valid from the initial release date of November 12, 2007. The expiration date is September 1, 2008. Program # 018-999-07-195-H01-P.
Nurses
The Dannemiller Memorial Educational Foundation is an approved provider of the California Board of Registered Nursing. Provider approved by the California Board of Registered Nursing, Provider Number 4229, for 1.2 contact hours.
RNs outside California must verify with their licensing agency for approval of this course.
Target Audience
This educational program is intended for pain management physicians, pharmacists and nurses involved in pain management.
Needs Assessment
Pain is the most common reason for patients seeking advice from their physician. One adult in five suffers from chronic pain. In general, musculoskeletal pain, often in the form of back disorders, represents the most common cause of chronic non-malignant pain (CNMP). Exposure to low social support, low social anchorage or low social participation significantly increases the odds of a high level of pain. Most patients do not attribute chronic musculoskeletal pain to injury, but those who do report significantly higher levels of emotional distress. Pain is the third leading reason for absence from work in the United States, where the problem of chronic pain translates into an annual expenditure of at least $50 billion. Assessment and treatment of back pain should be multidimensional. Accordingly, there is a need to educate healthcare professionals on the concepts and principles of treating back pain. (Reference: Katz, WA, Musculoskeletal pain and its socioeconomic implications. Clinical Rheumatology Feb. 2002)
Method Of Participation
The activity should take approximately 1 hour to complete. You should read the objectives and other CME information, proceed through the educational offering, and take the link to the registration for credit and post-test. The evaluation on the post-test site provides you with the opportunity to comment on the extent in which the educational needs were met, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and your views on future educational needs. To receive credit for this CME/CPE/CE activity, follow the instructions provided on the site. This credit is available through September 1, 2008. No credit will be given after this date.
Faculty Disclosure
It is the policy of the Dannemiller Memorial Educational Foundation to ensure balance, independence, objectivity, and scientific rigor in all sponsored educational activities. Any and all financial relationships between faculty and the commercial supporter of the CME activity, and products being discussed, is to be disclosed by the faculty to the attendees at the time of the activity.
Dr. Goli discloses that he he serves on the speakers bureau for Janssen, UCB, Novartis, Glaxo-SmithKline, Celger Principal Investigator, Clinical Trials-Pfizer, Celgene, and Elan. He has received funding for multi-center clinical trials from Merck, and is pending funding for investigator initiated studies from Celgene and UCB Pharma.
Dr. Finley discloses that she has nothing to disclose.
James Borwick, an independent Medical Writer, declares that he does not have a financial interest or other relationship with the commercial supporter of this activity or any manufacturer(s) of any commercial products discussed in this activity.
Unlabeled or Investigational Drug Disclosure
It is the policy of Dannemiller Memorial Educational Foundation that faculty disclose any unlabeled or investigational drugs discussed. Antidepressants are not approved for treatment of chronic back pain. Antiepileptics to include Tiagabine and topirimate are not approved for use in treatment of neuropathic back pain.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the Dannemiller Memorial Educational Foundation or Purdue Pharma. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Objectives
- Describe the general principles of back pain management.
- Discuss multidisciplinary approaches to back pain management including patient education, medication, physical medicine and psychological counseling.
- Review consensus statements, guidelines and policies on the treatment of back pain.
» Click Here To Begin This Article
|
